Browse by Medical Category
Tuesday, June 15, 2010
"Our results provide preclinical evidence for the rational combination of BRAF-targeted therapy and immunotherapy in the treatment of this most dangerous type of skin cancer," said lead researcher Jennifer A. Wargo, M.D., division of surgical oncology at Massachusetts General Hospital, Boston.
Link to full AACR release.
Katie Marquedant, 617 726-0337, email@example.com
Back to Top